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Title: Oral hygiene as a risk factor in infective endocarditis 
Abstract: There are many known associations between oral and systemic diseases. This 
review paper summarises the proposed mechanisms underlying the links between dental 
disease and cardiovascular disease before introducing recent research regarding bacteria-
platelet interactions. New protein factors have been identified on dental plaque bacteria. One 
of these, PadA, triggers blood to clot. This research provides new information about how 
Streptococcus bacteria and platelets interact and could lead to the development of new ways 
to control the formation of blood clots caused by microorganisms that access the 
bloodstream.  
Clinical relevance statement: This article aims to provide the whole dental team with an 
overview of bacteria-platelet interactions. This is of particular relevance to infective 
endocarditis and the recent change in wording to the NICE antibiotic prophylaxis guidelines 
in the UK. 
Brief objectives statement: The reader should understand the links between oral and 
cardiovascular disease and be able to discuss these associations with at-risk patients. 
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Introduction 
The mouth is often referred to as a window into the health of the body, but the idea of oral 
diseases being a risk factor for systemic diseases is not a new concept. The importance of 
oral hygiene was noted by the Ancient Greeks1 and Hippocrates recorded two cases where 
eradication of mouth infections relieved patients of rheumatic joint problems.2 The British 
surgeon William Hunter is regarded as one of the first in the 20th century to emphasise the 
role of oral sepsis in leading to generalised diseases3 and removal of infected teeth was 
common. In contrast, the second half of the 20th century saw increased conservation and 
restoration of teeth, with relatively little published about possible links between oral and 
systemic diseases. However a seminal study in 1989 reported that dental health was 
significantly worse in patients with acute myocardial infarction, after adjusting for risk 
factors.4 Subsequent papers re-ignited the debate and the turn of the 21st century saw a 
renewed scientific interest in the links between oral and systemic diseases, with increasing 
awareness that the mouth can act as a reservoir for pathogenic bacteria and their products. 
Of particular interest are the oral associations with cardiovascular disease, the most 
common cause of death worldwide. Classical risk factors (hypertension, 
hypercholesterolaemia, diabetes, ethnicity, smoking, family history, increased body weight, 
alcohol, lack of physical activity) only account for up to two thirds of cardiovascular disease 
cases5 and evidence is emerging that chronic oral infection and inflammation may be other 
risk factors.6 
The aim of this paper is to: 
1) Provide an overview of the proposed mechanisms linking oral and systemic diseases 
2) Summarise the known associations between oral bacteria and heart disease  
3) Describe recent research into interactions between oral bacteria and platelets, 
particularly relevant to infective endocarditis 
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Mechanisms linking oral and systemic diseases 
The reported associations between oral and systemic conditions are numerous and include 
the following diseases: heart disease6, ventilator-associated pneumonia7, adverse 
pregnancy outcome8, diabetes mellitus9, rheumatoid arthritis10, inflammatory bowel 
disease11, colorectal cancer12 and liver diseases13. 
Shared risk factors for oral disease and systemic diseases include age, male gender, alcohol 
consumption, smoking, hypertension, social isolation, stress and diabetes.4, 14 It is generally 
accepted that associations between oral and systemic diseases exist, but causation is more 
difficult to determine. In addition to shared risk factors, three possible mechanisms for the 
link between oral and systemic diseases have been proposed15, described below and in 
Figure 1. 
1) Bacteraemia and extra-oral site colonisation 
Entry of oral bacteria into the bloodstream (bacteraemia) during normal physiological 
activities may be as important in the pathogenesis of infective endocarditis (IE) as dentistry-
induced bacteraemia.16 Cumulative levels of bacteraemia have been calculated to be 
approximately 100,000 times higher during physiological activities, such as chewing or 
flossing, than after a single dental extraction.17 Oral streptococci, commonly implicated in IE, 
are often isolated from blood culture18 and periodontal pathogens have been found in 
atherosclerotic plaques.19 
2) Systemic injury as a result of bacterial toxins 
The production of toxins by oral bacteria can cause direct damage to the host. One well-
known example of an endotoxin is lipopolysaccharide (LPS), found in the outer membrane of 
Gram-negative bacteria. LPS can contribute to the induction of toxic shock, fever and 
apoptosis.20 
3) Systemic inflammation caused by the immunological response to oral 
microorganisms 
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Immune complexes form when soluble antigens react with circulating antibodies. The 
deposition of these immune complexes leads to chronic or acute inflammation, with raised 
levels of inflammatory mediators such as tumour necrosis factor-α, interleukin-1β and the 
vasodilator prostaglandin E2.21 Another acute-phase protein that activates the complement 
system during inflammation and is often used as a clinical marker of systemic inflammation 
is C-reactive protein (CRP).20 Several conditions have been associated with systemic 
inflammation caused by oral microorganisms, for example inflammatory bowel disease, 
uveitis and Behçet’s syndrome.21, 22 
Cardiovascular disease 
Cardiovascular disease is a term used to describe a spectrum of diseases of the circulatory 
system including myocardial infarction and stroke. Despite increased promotion of healthy 
lifestyles and widespread use of anti-cholesterol medication, cardiovascular disease 
continues to be a major burden in the UK.23 
Atherosclerosis is characterised by artery wall thickening as a result of accumulation of fatty 
material, but there is also a major inflammatory component.24 The development of an 
atherosclerotic lesion is shown in Figure 2. Periodontal disease may have a moderate 
association with atherosclerosis, and oral microorganisms have been detected in 
atherosclerotic lesions.19, 25 
Myocardial infarction 
Acute myocardial infarction (MI) is a clinical manifestation of atherosclerosis. Serum 
antibody levels to oral anaerobic bacteria have been found to be higher in MI subjects 
compared to a control group. Increased CRP levels were also found in the MI group.26 This 
adds to the body of evidence that inflammation caused by oral bacteria plays a significant 
role in atherosclerosis and MI.  
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Stroke 
Stroke is the loss of brain function due to a disturbance in brain blood supply, caused by 
thrombotic ischaemia or haemorrhage. Stroke is a recognised complication of IE27 and 
associations have been found between oral infections and stroke.28, 29 
Disseminated intravascular coagulation and sepsis 
Disseminated intravascular coagulation (DIC) is a life-threatening condition that occurs in 
response to tissue damage or infection. It results in fibrin deposition and obstruction in the 
microvasculature, causing organ dysfunction.30 It has been proposed that bacteraemia 
secondary to periodontal disease potentially contributes to the occurrence of a DIC-like 
disease presentation in the immunocompromised.31 Sepsis is a systemic inflammatory 
response to infection and occurs when a controlled initial response to an infection becomes 
exaggerated and deregulated.32 Sepsis may escalate to septic shock if untreated. Viridans 
group streptococci entering the circulation from the mouth can cause septic shock in 
immunosuppressed patients.33  
Infective endocarditis  
IE is characterised by the formation on heart valves of infected masses or vegetations 
containing bacteria, fibrin and platelets (Figure 3). There are over 2000 cases of IE in the UK 
annually and the incidence is rising.34 IE has a subtle clinical presentation, usually including 
fever, malaise and weight loss.34 The modified Duke criteria, including blood cultures and 
echocardiography, are used in diagnosis.17 The treatment of IE patients is coordinated by a 
multi-disciplinary team and aims to eradicate the implicated microorganisms by antimicrobial 
drug treatment alone, or in conjunction with surgery. The use of antimicrobials poses several 
problems, such as poor penetration into vegetations, resulting in the need for high serum 
concentrations of antimicrobial agents.35 Bacterial resistance to antibiotics is also increasing, 
making IE a difficult condition to treat successfully. Mortality is high with 15-20% of IE 
patients dying during their initial hospital admission.34 Of those who survive, 10-15% die 
during the following year.34  
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Endocarditis can be classified according to the site (right or left-sided), type of valve involved 
(native or prosthetic), or timing (early or late). Left-sided native valve endocarditis is the most 
common form of IE and occurs in people with pre-existing lesions of the heart, such as 
congenital heart defects or rheumatic fever-induced damage.  
Streptococci, enterococci and Staphylococcus aureus as a group are responsible for more 
than 80% of cases of IE36 and oral viridans group streptococci are causative agents in 35-
45% of cases of IE.37 Oral streptococci are the predominant IE pathogens in the general 
population whereas S. aureus is more often found in healthcare-associated IE.17 New “at 
risk” groups have emerged in recent years, such as IV drug users, patients with valve 
sclerosis and haemodialysis patients.36 
Platelets  
Platelets are anucleate cell fragments, formed from their precursor megakaryocytes in the 
bone marrow (Figure 4). They are approximately 2-3 µm in diameter and have a lifespan of 
5-9 days.38 The platelet cytoplasm contains the endoplasmic reticulum, Golgi apparatus, 
mitochondria, granules and contractile proteins.39 The granules are stores of important 
clotting mediators such as adenosine diphosphate, serotonin, Ca2+ (dense granules), 
fibrinogen, vitronectin and von Willebrand factor (α-granules).40 A large number of platelet 
membrane receptors are necessary for haemostasis. Of particular note are the integrins, a 
family of heterodimers that mediate cell-cell or cell-substratum interactions by linking 
extracellular signals to intracellular pathways.41 Platelets typically circulate in a resting state 
at the periphery of the blood vessel, ready to respond to vessel wall damage. When they 
encounter exposed subendothelial tissues at the site of vessel wall damage, they adhere, 
become activated, aggregate and recruit other platelets to the site to form the platelet clot. 
Being the first cells present at injury sites also means that platelets are ideally placed to 
recruit immune cells. Evidence is emerging of the critical importance of platelets in 
orchestrating the immune response.42  
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Bacteria-platelet interactions 
The cardiovascular system is normally a sterile environment in health. When bacteria enter 
the circulation, platelets can direct the immune response to manage exposure to bacterial 
pathogens. Bacteria-platelet binding triggers platelet activation and the secretion of 
antimicrobial peptides from platelets, although some bacteria have become resistant to 
these peptides.43 The immune platelet response in itself can become part of the pathogenic 
process leading to the formation of septic thrombi. Bacteria-induced platelet activation and 
aggregation allows bacteria to survive in infected thrombi, effectively hidden from the rest of 
the immune system by the platelet clot. This has been described as a “Trojan Horse” effect 
for streptococcal-platelet interactions.44 Some bacteria are able to mediate the formation of 
unstable platelet aggregates from which microbial cells subsequently escape, allowing them 
to evade host immune responses and disseminate through the circulation during invasive 
infection.45  
The study of bacteria-platelet interactions only gained momentum in the last 40 years 
following the publication of a series of papers by Clawson et al.46-49 Bacteria can interact with 
platelets via multiple mechanisms and one microorganism may produce several factors 
capable of interacting with platelets simultaneously. This makes it difficult to study the role of 
individual receptors. However, three general modes of interaction between bacteria and 
platelets (Figure 5) have been described.50  
1) Direct binding of platelet receptor to bacterial surface component 
The direct interaction of a specific bacterial protein with target platelet receptors leads to 
platelet adhesion or activation. Streptococcus serine-rich repeat proteins bind directly to 
platelet glycoprotein Ib and mediate platelet rolling and adhesion under flow conditions.51 
2) Indirect binding of platelet receptor to bacterium via a bridging plasma protein such 
as fibrinogen or complement 
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An indirect interaction with platelets is shown by S. aureus Clumping factor A (ClfA). 
Simultaneous binding of ClfA to fibrinogen and antibody, which interacts with integrin αIIbβ3 
and FcγRIIa on the platelet surface, is essential for platelet aggregate formation.52 
3) Secretion of bacterial toxins that interact with platelets 
S. aureus releases a toxin known as α-toxin that causes platelet aggregation and shape 
change.53 This toxin has more recently been shown to induce production of B cell 
lymphoma-3 in platelets, a factor thought to be important in the development of IE.54  
Streptococcus gordonii-platelet interactions 
Oral streptococci are major mediators of IE, and have numerous surface proteins capable of 
modulating attachment to surfaces within the oral cavity, endothelial tissue, extracellular 
matrix and platelets.55 The interactions of platelets with Streptococcus gordonii, a ubiquitous 
oral bacterium often implicated in IE18, have been the subject of much research in recent 
years by our laboratories. S. gordonii has been shown to interact with platelets directly (see 
Mechanism 1 above). Surface factors Hsa (serine-rich repeat polypeptide) and SspA/SspB 
(antigen I/II family polypeptides) play critical roles in mediating platelet interactions.55-58 In a 
rabbit model of endocarditis, mutation of the hsa gene alone is sufficient to ablate formation 
of infective vegetations on heart valves (Figure 6).  
More recently, our studies have identified a new protein (PadA) which binds and activates 
platelets, causing them to contribute to undesirable functions including blood clotting.59-61 
Tripeptide motifs, including an NGR (Asparagine-Glycine-Arginine) motif that is also found in 
human blood protein fibrinogen, are responsible for PadA binding to activated platelets.62 
The platelet receptor implicated in PadA binding is integrin αIIbβ3. Together this information 
suggests that the bacteria are mimicking fibrinogen, effectively fooling platelets into 
activating and triggering the clotting process inappropriately. It also appears that Hsa and 
PadA may be reliant on each other for mediating bacterial interactions with platelets and 
extracellular matrix proteins such as fibronectin and vitronectin.62 Further recent evidence 
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shows that antibodies targeting Hsa and PadA prevent platelet aggregation and protect 
against S. gordonii-induced endocarditis in a rat model.63 
Proteins with similarities to PadA have been identified in a number of IE pathogens 
(Streptococcus mitis, Streptococcus oralis, Enterococcus faecalis). It will be important to 
determine if there is a common functional mechanism that could be targeted to control 
infection-induced cardiovascular disease. It has already been suggested that PadA and Hsa 
in S. gordonii could be promising vaccine candidates against viridans group streptococci-
induced IE.63 
Clinical implications 
The appropriate management of dental patients at risk of IE has been a controversial topic 
over recent years. An increase in IE incidence has occurred after the change in practice 
regarding antibiotic prophylaxis recommended by NICE in 2008.37, 64 In 2015, NICE reviewed 
the guidelines and announced there was insufficient evidence to warrant a change, 
generating considerable debate in the literature.34, 65-71 In addition, there were changes in the 
law on informed consent in the UK.72 In July 2016, a change in the wording of the NICE 
guidelines was announced64 meaning that in individual cases, antibiotic prophylaxis may be 
appropriate. As discussed elsewhere73, the current situation still leaves considerable 
challenges for dentists when faced with implementing the guidelines. 
A qualitative study from the USA in 2013 found that dentists were keen to use the 
associations between oral and systemic diseases as a motivating factor for patients to 
maintain good oral health.74 In fact the Editors’ Consensus Report of The American Journal 
of Cardiology and Journal of Periodontology suggest that patients with moderate to severe 
periodontal disease should be informed about the increased risk of cardiovascular disease.75 
In addition, they state that a periodontal assessment should be considered in patients with 
cardiovascular disease who have tooth loss and unexplained high levels of CRP or other 
inflammatory markers.75 Certainly in the case of IE, dentists should reinforce the importance 
of excellent oral hygiene to patients at risk of developing the condition and encourage 
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regular dental reviews.73 At-risk patients and dentists should all be aware of the symptoms of 
endocarditis34 and refer early when appropriate. 
Conclusion 
The importance of maintaining good oral health for systemic health is an ancient concept but 
just as relevant today. Direct or indirect mechanisms have been proposed for links between 
oral bacteria and systemic diseases. Recent research has shown direct effects of oral 
bacteria on platelet function, leading to platelet activation and formation of infected clots. 
These new discoveries explain how oral microbes stimulate formation of vegetations and this 
work will lead to the development of new ways to control or prevent the formation of infective 
blood clots. At-risk patients and dentists should be aware of the recent change in wording to 
the antibiotic prophylaxis guidelines and be knowledgeable about early IE symptoms. Two 
and a half centuries after the Ancient Greeks took notice, it is time for the dental and medical 
professions to raise public awareness about the importance of good oral hygiene to stay 
healthy.  
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Figure legends 
 
Figure 1 Diagrammatic representation of the mechanisms linking oral and systemic 
diseases 
VAP = ventilator-associated pneumonia; IBD = inflammatory bowel disease; APO = adverse 
pregnancy outcome; RA = rheumatoid arthritis 
 
Figure 2 The development of an atherosclerotic lesion (adapted from Libby et al., 
2011) 
A) The normal artery. Three layers are found: the tunica intima, which is lined by endothelial 
cells; the tunica media, which comprises smooth muscle cells in an extracellular matrix; and 
the tunica adventitia, which contains mast cells and fibroblasts. B) Initial atherosclerotic 
changes. Activated endothelial cells capture monocytes and these migrate into the tunica 
intima. They mature to become macrophages and when they take up lipid they become 
known as foam cells. C) Lesion progression. Smooth muscle cells migrate to the tunica 
intima and collagen and other extracellular matrix molecules are produced. Cholesterol 
crystals and microvessels form and macrophages and smooth muscle cells undergo 
apoptosis. D) Disruption of atherosclerotic plaque and thrombosis. The lipid core is an 
accumulation of extracellular lipid from dead cells. The fibrous cap of the plaque ruptures 
and formation of a thrombus is triggered. 
 
Figure 3 Diagrammatic representation of the heart 
The four heart valves are highlighted and infected vegetations are shown at the mitral valve 
and at a non-valve endocardial site. The direction of blood flow is denoted by arrows. The 
heart valves control the flow of the blood through the heart chambers. Pressure differences 
generated within the heart, along with muscle fibres, control the opening and closing of the 
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valves. Oxygen-poor blood from the body enters the heart from the inferior and superior 
vena cava vessels into the right atrium. Blood flows into the right ventricle from the right 
atrium through the tricuspid valve, which then closes when the ventricle is full. When the 
right ventricle contracts, blood leaves the heart through the pulmonary valve entering the 
pulmonary arteries, where it continues to the lungs for oxygenation. Oxygen-rich blood 
returns to the left atrium from the pulmonary veins. Blood enters the left ventricle through the 
mitral valve. When the left ventricle contracts blood enters the aorta through the aortic valve. 
IE vegetations can be found at each of the valve sites highlighted or at multiple valve sites 
simultaneously. Both native and prosthetic valves can be affected. 
 
Figure 4 The ultrastructure of a platelet 
Platelets are anucleate cell fragments, measuring 2-3 µm in diameter. The trilaminar 
membrane maintains the integrity of the cytoplasm and invaginations of the membrane form 
the canalicular system. Dense granules contain adenosine diphosphate, serotonin and Ca2+ 
ions, and α-granules contain fibrinogen, vitronectin and von Willebrand factor. 
 
Figure 5 Summary of the interactions between bacteria and platelets 
a) Direct interaction 
b) Indirect interaction  
c) Bacterial toxin-mediated interaction 
 
Streptococcus gordonii employs the direct interaction (a); Streptococcus pyogenes utilises 
the indirect bridging mechanism (b); Staphylococcus aureus employs all three mechanisms 
(a, b and c). 
Figure 6 Infective endocarditis in a rabbit model  
Heart valve specimens from a catheter-induced rabbit model of IE. Panel A, The white arrow 
indicates blood clot formation, and the black arrows denote vegetations present on valve 
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leaflets resulting from systemic infection by S. gordonii. Panel B, Bacteria without the hsa 
gene appear not to induce IE.  
 
 
